Dendreon's Provenge becomes first therapeutic cancer vaccine to be approved in US
This article was originally published in Scrip
Executive Summary
The first therapeutic cancer vaccine has been approved in the US by the FDA, Dendreon's Provenge (sipuleucel-T). The long-awaited development will boost the field of cancer immunotherapy, a novel approach that stimulates the immune system to fight the disease.